Macrolides: The Plug Is Out  by Gamerdinger, Martin & Deuerling, Elke
Leading Edge
PreviewsMacrolides: The Plug Is Out
Martin Gamerdinger1 and Elke Deuerling1,*
1Molecular Microbiology, Department of Biology, University of Konstanz, 78457 Konstanz, Germany
*Correspondence: elke.deuerling@uni-konstanz.de
http://dx.doi.org/10.1016/j.cell.2012.10.015
Macrolide antibiotics are thought to clog up the ribosomal tunnel and thereby block general
protein synthesis. By using a combination of elegant in vivo and in vitro approaches, Kannan
et al. show that the inhibitory action of these drugs on bacterial protein synthesis is selective rather
than global.The discovery of erythromycin in the
1950s was the starting point for the devel-
opment of the clinically important antibi-
otics of the macrolide class. Macrolides
consist of 14- to 16-membered lactone
rings to which various sugar moieties are
attached. These drugs specifically inhibit
the activity of the bacterial protein bio-
synthetic machinery, the ribosome. The
cellular target of macrolides is a narrow
tunnel of the large ribosomal subunit
known as the nascent peptide exit tunnel
(NPET). Nascent polypeptides synthe-
sized by ribosomes must exit through
this ribosomal ‘‘birth canal’’ to reach the
extraribosomal cellular environment (Ban
et al., 2000; Milligan and Unwin, 1986;
Yonath et al., 1987). Binding of macro-
lides to the inner wall of the NPET is
thought to occlude the tunnel lumen,
leading to a complete shut-off of protein
synthesis (Schlu¨nzen et al., 2001). In
contrast to this prevailing ‘‘plug-in-the-
bottle’’ model of macrolide action, in this
issue, Kannan et al. (2012) demonstrate
that a distinct subset of polypeptides
can slither through the drug-obstructed
tunnel and that the inhibition of protein
synthesis by macrolides is protein selec-
tive rather than general.
The bacterial ribosome is a primary
target of antibiotics. The binding sites
and the modes of action on ribosomes,
however, are different among the different
antibiotic classes. Many clinically relevant
antibiotics, like chloramphenicol and the
lincosamides, directly interact with and
block the ribosomal peptidyl transferase
center (PTC), where amino acids are
assembled into proteins by peptide
bond formation (Schlu¨nzen et al., 2001).
Antibiotics of themacrolide (and streptog-
ramin B) class are unique among theribosome-targeting antibiotics, as they
do not block peptide bond formation in
the PTC directly. Macrolides bind within
the NPET at the mouth of the exit tunnel
between the PTC and a tunnel constric-
tion formed by the extended loops of the
ribosomal proteins L22 and L4 (Figure 1)
(Hansen et al., 2002; Schlu¨nzen et al.,
2001; Tu et al., 2005). This portion of the
tunnel is the narrowest, and the prevailing
view of macrolide action is that the drugs
form an impassable barrier at the tunnel
constriction that blocks the path and,
thus, the synthesis of all nascent polypep-
tide chains. Crystallographic studies of
macrolide-bound ribosomes confirm that
macrolide binding dramatically narrows
the tunnel (Schlu¨nzen et al., 2001). How-
ever, after modeling short nascent pep-
tides into the erythromycin-obstructed
NPET, Steitz and coworkers (Tu et al.,
2005) hypothesized that there is poten-
tially still enough room for a peptide to
pass the antibiotic. In line with this model,
Kannan et al. provide compelling evi-
dence that a distinct subset of proteins
can indeed efficiently bypass the macro-
lide-obstructed tunnel in vivo and that
full-size proteins can be synthesized by
drug-bound ribosomes. Moreover, Man-
kin and coworkers (Kannan et al., 2012)
show that not all proteins that bypass
the antibiotic with their N-terminus are
translated to full size. Elongation, in
particular of larger polypeptide chains,
can be arrested by macrolides also at
later stages of translation, resulting in
the formation of large truncated proteins
(Figure 1). The finding that macrolides
allow selective synthesis of full-size and
truncated proteins in bacteria could be
a highly important aspect contributing to
the bacterial toxicity of this antibioticCell 151class. The unregulated residual and frag-
mented translation of polypeptides very
likely leads to a dramatic imbalance of
the cellular proteome that potentially
impairs essential survival pathways more
rapidly than the global shut-down of
protein synthesis. Consistent with this
view, Kannan et al. demonstrate that
the more potent and newest generation
of macrolide antibiotics—the ketolide
group—obstruct the ribosomal tunnel
less tightly than macrolides, allowing
more residual protein synthesis. How-
ever, further experimental data are clearly
needed before drawing the conclusion
that selective protein synthesis inhibitors
are killing bacteria more efficiently than
global inhibitors. If verified, this might
open up an entirely new direction for anti-
biotic drug development.
What are the general determinants that
enable nascent proteins to slither through
the macrolide-obstructed ribosomal exit
tunnel? We don’t have a definitive answer
yet, but Kannan et al. have made a great
effort to define the features that confer
macrolide resistance at least to some
proteins. It turns out that the bypass
efficiency depends on key sequences in
the N termini of proteins. A peptide
segment composed of the first twelve
N-terminal amino acids is sufficient to
mediate the bypass of the protein through
the drug-obstructed tunnel. Fusion of this
peptide segment to the N terminus of a
short macrolide-sensitive protein results
in its full translation by the drug-bound
ribosomes. This finding is indeed remark-
able, as the newly resistant protein still
has the ‘‘problematic’’ macrolide-sensi-
tive protein sequence of its original N
terminus to be translated. This indicates
that, once a nascent peptide slips by the, October 26, 2012 ª2012 Elsevier Inc. 469
Figure 1. Selective Blockade of Protein Synthesis by Macrolide Antibiotics
Nascent polypeptides in themacrolide-obstructed ribosomal tunnel havemultiple potential fates. The side
view of the 50S large ribosomal subunit (cut in half) shows the binding site of the macrolide antibiotics
(yellow) within the nascent peptide exit tunnel (NPET). Macrolides specifically bind at the inner wall of the
exit tunnel proximal to the peptidyl transferase center (PTC) and distal to a tunnel constriction, where loops
of the ribosomal proteins L4 and L22 protrude into the tunnel lumen. Most nascent peptides have critical
protein sequences at their N terminus (red cross) that cannot pass the macrolide-obstructed tunnel part
resulting in early translation arrest. However, some proteins feature distinct physicochemical or structural
properties at the N terminus (green arrow) that allow the growing polypeptide to pass by the antibiotic. The
synthesis of polypeptides that bypass the macrolide molecule initially with their N terminus can either be
arrested at later stages of translationwhen critical downstream sequences (red cross) enter themacrolide-
bound tunnel portion or the proteins can be translated to full size.drug with its N terminus, a decision is
made that allows the translation of the
protein in the macrolide-obstructed470 Cell 151, October 26, 2012 ª2012 Elsevitunnel. However, there is no absolute
rule for this N-terminal bypass, as macro-
lides can also induce late translationer Inc.arrest when critical downstream se-
quences enter the ribosomal tunnel.
Kannan et al. elegantly show that the
phenomenon of macrolide-dependent
late translation arrest depends on the
structure of the nascent peptide proximal
to the PTC and that it very likely involves
interactions of the nascent peptide with
the ribosomal exit tunnel as well as with
the macrolide molecule.
The study of Kannan et al. addresses
a very important and interesting topic:
the communication of nascent peptides
with the inner ribosomal landscape and
the contribution thereof to cellular physi-
ology. The inner wall of the NPET is essen-
tially built of 23S ribosomal RNA and is
thus lined with hydrated polar groups
and very few hydrophobic surfaces (Ban
et al., 2000). This allows the accommoda-
tion and the successful passage of most
peptide sequences without regard to their
chemical properties. However, the NPET
is not a neutral conduit. Previous studies
have shown that this tunnel is an impor-
tant functional compartment that moni-
tors the structure of the nascent polypep-
tide. Some nascent peptide segments
interact with the ribosomal interior com-
ponents proximal to the PTC and dramat-
ically affect the rate of elongation or even
terminate translation. The phenomenon
of programmed translation arrest by
nascent peptides has been identified not
only in bacteria, but also in eukaryotes
(Ito et al., 2010). A growing body of evi-
dence indicates that nascent peptide-
mediated translation arrest plays an
important role in cellular physiology.
Such regulatory systems that use ribo-
some stalling sequences are in many
cases activated by small metabolites (for
instance, tryptophan or arginine) oper-
ating in negative feedback loops (Fang
et al., 2004; Gong and Yanofsky, 2002).
Although the binding site of these metab-
olites on ribosomes is yet to be deter-
mined, these examples clearly show us
that small molecules can modulate the
discriminatory properties of the ribosomal
exit tunnel. The study by Kannan et al.
extends our knowledge of this phenom-
enon and suggests that small drug-like
molecules that bind in the NPET cause
structural changes and selective syn-
thesis of a distinct subset of proteins.
Targeted modification of the ribosomal
tunnel resulting in selective protein
synthesis opens new avenues in biotech-
nology and medicine, far beyond the
development of new antibiotics.
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A surprising link between innate immunity and nuclear reprogramming is reported by Lee et al.; this
discovery may boost the efficiency of stem cell production.Innate immunity primarily involves germ-
line-encoded receptors that recognize
conserved microbial structures, trigger-
ing signaling pathways that induce the
expression of a wide range of proteins
critical for disease resistance. Despite
its ubiquity and importance, the link
between innate immunity and the induc-
tion of pluripotent stem cells uncovered
by Lee et al. (2012) in this issue of Cell
is far from obvious. They demonstrate
that activation of toll-like receptor-3
(TLR3) causes changes in expression of
epigenetic modifiers, thereby facilitating
nuclear reprogramming in the presence
of the transcription factor cocktail con-
sisting of Oct4, Sox2, Klf4, and c-Myc
(Figure 1). This new approach could opti-
mize the induction of pluripotent stem
cells from somatic cells and may pro-
vide a whole new means for stem cell
production.
Landmark studies by Yamanaka (re-
warded with the Nobel Prize for Medicine
of Physiology in 2012) and colleaguesdemonstrated that the expression of four
transcription factors, Oct4, Sox2, Klf4,
and c-Myc (OSKM), could induce pluripo-
tency in somatic cells such as fibroblasts
(Takahashi et al., 2007). This OSKM
protocol was an important breakthrough
in stem cell research, but the mechanism
was uncertain. Retroviral expression of
the proteins led to concerns about inte-
gration into the host genome that might
dysregulate expression of other important
host genes and have deleterious effects,
including cellular transformation. The
OSKM proteins themselves, when ren-
dered cell permeable, could achieve the
same effect, although curiously with
much lower efficiency (Cho et al., 2010).
Lee et al. (2012) address this inefficiency
by first comparing the ability of retrovirally
encoded Sox2 (as a sample OSKM
protein) to cell-permeant Sox2 to induce
pluripotency. Both were applied to fibro-
blasts and downstream targets of Sox2,
such as Jarid2, as well as markers of
nuclear reprogramming, such as Nanog,were measured. Both types of response
are enhanced in response to retrovirally
encoded Sox2, whereas cell-permeant
Sox2 is much less effective. A similar
difference is observed with Oct4. The
authors hypothesized that an intrinsic
feature of viral particles might be respon-
sible for the different efficiencies. They
confirm this by demonstrating that the
viral vector alone, which does not encode
Sox2, when combined with cell-permeant
Sox2 could induce similar gene expres-
sion changes as that induced by the
vector when it encoded Sox2.
Given that certain TLRs sense nucleic
acids (usually derived from microbes),
the authors wondered if TLR activation
might be involved. They examined TLR3
because this is known to sense viral RNA
(Alexopoulou et al., 2001) and so might
sense the retroviral vector. TLR3 signals
via the adaptor protein Trif (Yamamoto
et al., 2003), and so the authors knocked
down TLR3 or Trif and found inhibition of
the induction of pluripotency genes by, October 26, 2012 ª2012 Elsevier Inc. 471
